Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026
Rhythm Pharmaceuticals presented multiple new data sets at ENDO 2026 demonstrating robust efficacy of its MC4R agonists in rare obesity disorders. Setmelanotide achieved a mean BMI reduction of 18.9% in patients with acquired hypothalamic obesity over 2.5 years, while oral bivamelagon showed BMI reductions ranging from 6.7% to 16.6% at one year.
Key figures
- Drug Name
- setmelanotide, bivamelagon
- Phase Of Trial
- Phase 2
- Pws trial status
- Phase 2 interim results announced
- Bbs mean weight loss adults
- -9.8%
- Setmelanotide ho bmi reduction
- -18.9%
- Bbs adults weight loss ge 10pct
- 62%
- Bivamelagon ho bmi reduction max
- -16.6%
- Bivamelagon ho bmi reduction min
- -6.7%
- Setmelanotide ho bmi zscore change
- -1.60
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.